#United States #New York #Pomerantz Law Firm #Investor Claims #Acadia Pharmaceuticals

Pomerantz Law Firm Investigates Claims on Behalf of Investors in ACADIA Pharmaceuticals Inc.

In a significant move highlighting shareholder rights, the Pomerantz Law Firm has launched an investigation into potential claims involving investors of ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD). The firm is examining whether Acadia, along with certain officers and directors, has engaged in any unlawful business practices, which may have negatively impacted investors.

This investigation has come to the forefront following a troubling announcement made by Acadia on September 24, 2025. The company disclosed the results from the Phase 3 COMPASS PWS trial that focused on the effectiveness and safety of its drug, intranasal carbetocin (ACP-101), in patients with Prader-Willi syndrome (PWS). Unfortunately, the trial results revealed that the drug failed to show any statistically significant improvement over a placebo on the primary endpoint, which was a change in the Hyperphagia Questionnaire for Clinical Trials (HQ-CT) over 12 weeks. Moreover, the company indicated that there would be no further investigation into intranasal carbetocin following these results.

The announcement led to a severe reaction in the stock market. Acadia's stock price plummeted by $2.34 per share, marking a decline of approximately 9.92%, with the shares closing at $21.26 on that day. For many investors, this sharp decline raises concerns not only about the financial implications but also about the transparency and practices within the company.

Potential investors who wish to join the class action are encouraged to contact the Pomerantz Law Firm, specifically reaching out to Danielle Peyton at [email protected] or at 646-581-9980, extension 7980. The firm is known for its extensive work in securities class actions and has a solid track record of advocating for victims of corporate misconduct.

Pomerantz LLP, headquartered in New York, has built a reputation over its 85 years of operation for taking on significant cases in securities fraud, breaches of fiduciary duty, and other corporate misconduct. Founded by Abraham L. Pomerantz, often considered a pioneer in class action litigation, the firm has successfully recovered numerous multimillion-dollar settlements for affected investors and continues to uphold the rights of shareholders.

In light of recent developments, it remains crucial for investors to remain vigilant regarding their investments in ACADIA Pharmaceuticals. The firm’s investigation is a reminder of the importance of corporate governance and accountability in protecting investor interests. As the situation develops, stakeholders will be keenly observing the actions of Acadia's leadership in response to investor grievances and the broader implications for the pharmaceutical industry.

For ongoing updates regarding the situation, investors and interested parties are advised to monitor communications from both the Pomerantz Law Firm and ACADIA Pharmaceuticals. The outcome of this investigation could yield far-reaching implications for how public companies approach transparency and shareholder relations, especially in highly specialized fields like pharmaceuticals.